BACKGROUND: In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab prolonged overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression ≥1% versus chemotherapy. We report results from CheckMate 227 Part 2, which evaluated nivolumab plus chemotherapy versus chemotherapy in patients with metastatic NSCLC regardless of tumor PD-L1 expression. PATIENTS AND METHODS: Seven hundred and fifty-five patients with systemic therapy-naive, stage IV/recurrent NSCLC without EGFR mutations or ALK alterations were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus chemotherapy or chemotherapy. Primary endpoint was OS with nivolumab plus chemotherapy versus chemotherapy in patients with nonsquamous NSCLC. OS in all randomized patients was a hierarchically tested secondary endpoint. RESULTS: At 19.5 months' minimum follow-up, no significant improvement in OS was seen with nivolumab plus chemotherapy versus chemotherapy in patients with nonsquamous NSCLC [median OS 18.8 versus 15.6 months, hazard ratio (HR) 0.86, 95.62% confidence interval (CI) 0.69-1.08, P = 0.1859]. Descriptive analyses showed OS improvement with nivolumab plus chemotherapy versus chemotherapy in all randomized patients (median OS 18.3 versus 14.7 months, HR 0.81, 95.62% CI 0.67-0.97) and in an exploratory analysis in squamous NSCLC (median OS 18.3 versus 12.0 months, HR 0.69, 95% CI 0.50-0.97). A trend toward improved OS was seen with nivolumab plus chemotherapy versus chemotherapy, regardless of the tumor mutation status of STK11 or TP53, regardless of tumor mutational burden, and in patients with intermediate/poor Lung Immune Prognostic Index scores. Safety with nivolumab plus chemotherapy was consistent with previous reports of first-line settings. CONCLUSIONS: CheckMate 227 Part 2 did not meet the primary endpoint of OS with nivolumab plus chemotherapy versus chemotherapy in patients with metastatic nonsquamous NSCLC. Descriptive analyses showed prolonged OS with nivolumab plus chemotherapy in all-randomized and squamous NSCLC populations, suggesting that this combination may benefit patients with untreated metastatic NSCLC.

Blacktown Hospital Sydney Australia

Bristol Myers Squibb Princeton USA

Clínica Viedma Viedma Argentina

Fox Chase Cancer Center Philadelphia USA

Guangdong Lung Cancer Institute Guangdong Provincial People's Hospital Southern Medical University Guangdong China

Hôpital Sainte Musse Toulon France

Hospital Universitario 12 de Octubre Universidad Complutense and CiberOnc Madrid Spain

Institutul Oncologic Prof Dr Ion Chiricuţă and UNF Iuliu Haţieganu University Cluj Napoca Romania

Johns Hopkins The Sidney Kimmel Comprehensive Cancer Center Baltimore USA

Lung Clinic Grosshansdorf Airway Research Center North German Center of Lung Research Grosshansdorf Germany

Maria Skłodowska Curie National Research Institute of Oncology Warsaw Poland

Princess Alexandra Hospital and Queensland University of Technology Brisbane Australia

Sun Yat Sen University Cancer Center Guangdong China

Thomayer Hospital Charles University Prague Czech Republic

Winship Cancer Institute Emory University Atlanta USA

Zhejiang Cancer Hospital Hangzhou China

Zobrazit více v PubMed

Brahmer J.R., Lee J.S., Ciuleanu T.E., et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer in CheckMate 227. J Clin Oncol. 2023;41(6):1200–1202. PubMed PMC

de Castro G., Kudaba I., Wu Y.-L., et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥ 1% in the KEYNOTE-042 study. J Clin Oncol. 2023;41(11):1986–1991. PubMed PMC

Paz-Ares L., Ciuleanu T.-E., Cobo M., et al. First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations. J Thorac Oncol. 2022;18(2):P204–P222.

Reck M., Rodríguez-Abreu D., Robinson A.G., et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol. 2021;39(21):2339–2349. PubMed PMC

Garassino M.C., Gadgeel S.M., Speranza G., et al. KEYNOTE-189 5-year update: first-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC. Ann Oncol. 2022;33(suppl 7):S448–S554.

Novello S., Kowalski D.M., Luft A., et al. Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer: 5 year update of the phase III KEYNOTE-407 study. J Clin Oncol. 2023;41(11):1999–2006. PubMed PMC

Borghaei H., Gettinger S., Vokes E.E., et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–733. PubMed PMC

Juergens R., Hellmann M., Brahmer J., et al. First-line nivolumab plus platinum-based doublet chemotherapy for advanced NSCLC: CheckMate 012 3-year update. J Thorac Oncol. 2017;12:S1792–S1793.

Rizvi N.A., Hellmann M.D., Brahmer J.R., et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non–small-cell lung cancer. J Clin Oncol. 2016;34(25):2969–2979. PubMed PMC

Hellmann M.D., Rizvi N.A., Goldman J.W., et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41. PubMed PMC

Ready N., Hellmann M.D., Awad M.M., et al. First-line nivolumab plus ipilimumab in advanced non–small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J Clin Oncol. 2019;37(12):992–1000. PubMed PMC

Hellmann M.D., Paz-Ares L., Bernabe Caro R.B., et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–2031. PubMed

Hellmann M.D., Ciuleanu T.E., Pluzanski A., et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104. PubMed PMC

Opdivo® (nivolumab) [prescribing information]. Princeton, NJ: Bristol Myers Squibb; 2023. Available at https://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed March 8, 2023.

Ono Pharmaceutical Co, Ltd OPDIVO® (nivolumab) intravenous infusion approved for first-line treatment of unresectable advanced of recurrent non-small cell lung cancer in South Korea. https://www.ono-pharma.com/sites/default/files/en/news/press/sm_cn201217.pdf Available at.

Bristol Myers Squibb Argentina Prospecto de prescripción OPDIVO® (nivolumab). Buenos Aires, Argentina. https://www.bms.com/assets/bms/latam/documents/meds/medicine-prospecto/argentina/ar-es-opdivo-Mar%202020-May%202021-pi-clean.pdf Available at.

Skoulidis F., Heymach J.V. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19(9):495–509. PubMed PMC

Peters S., Creelan B., Hellmann M.D., et al. Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage IV or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate 026. Cancer Res. 2017;77(suppl 13):CT082.

Paz-Ares L., Ciuleanu T., Cobo M., et al. 98O First-line nivolumab (NIVO)+ ipilimumab (IPI)+ 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA. J Thoracic Oncol. 2021;16(suppl 4):S750–S751.

Huang L., Han H., Zhou L., et al. Evaluation of the Lung Immune Prognostic Index in non-small cell lung cancer patients treated with systemic therapy: a retrospective study and meta-analysis. Front Oncol. 2021;11 PubMed PMC

Mezquita L., Auclin E., Ferrara R., et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351–357. PubMed PMC

Benitez J.C., Recondo G., Rassy E., Mezquita L. The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. Q J Nucl Med Mol Imaging. 2020;64(2):162–174. PubMed

Hopkins A.M., Kichenadasse G., Abuhelwa A.Y., McKinnon R.A., Rowland A., Sorich M.J. Value of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy: subgroup analysis of the IMPOWER150 trial. Cancers (Basel) 2021;13(5):1176. PubMed PMC

Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655. PubMed

Foundation Medicine Inc. FoundationOne CDx technical information. June 2020. https://downloads.ctfassets.net/w98cd481qyp0/41rJj28gFwtxCwHQxopaEb/73f160765c72215040200ad245db62e4/FoundationOne_CDx_Label_Technical_Info.pdf Available at.

Ramalingam S.S., Hellmann M.D., Awad M.M., et al. Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568. Cancer Res. 2018;78(suppl 13):CT078.

Gandhi L., Rodriguez-Abreu D., Gadgeel S., et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–2092. PubMed

West H., McCleod M., Hussein M., et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–937. PubMed

Nishio M., Barlesi F., West H., et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial. J Thorac Oncol. 2021;16(4):653–664. PubMed

Lang Y., Sun Y., Wang Z., et al. Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. J Thorac Oncol. 2021;16(12):2109–2120. PubMed

Paz-Ares L., Vicente D., Tafreshi A., et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol. 2020;15(10):1657–1669. PubMed

Ramalingam S., Balli D., Ciuleanu T.-E., et al. Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 Part 1: efficacy by KRAS, STK11, and KEAP1 mutation status. Ann Oncol. 2021;32(suppl 7):S1373–S1391.

Garassino M.C., Gadgeel S., Novello S., et al. Associations of tissue tumor mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic NSCLC. JTO Clin Res Rep. 2022;4(1) PubMed PMC

Tanaka S., Uchino J., Yokoi T., et al. Prognostic nutritional index and lung immune prognostic index as prognostic predictors for combination therapies of immune checkpoint inhibitors and cytotoxic anticancer chemotherapy for patients with advanced non-small cell lung cancer. Diagnostics (Basel) 2022;12(2):423. PubMed PMC

Auclin E., Vuagnat P., Smolenschi C., et al. Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors. Cancers (Basel) 2021;13(15):3776. PubMed PMC

Ruiz-Bañobre J., Areses-Manrique M.C., Mosquera-Martinez J., et al. Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Transl Lung Cancer Res. 2019;8(6):1078–1085. PubMed PMC

Ali W.A.S., Hui P., Ma Y., et al. Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy. Ann Transl Med. 2021;9(22):1639. PubMed PMC

Socinski M.A., Jotte R.M., Cappuzzo F., et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. PubMed

Keytruda® (pembrolizumab) [prescribing information]. Rahway, NJ: Merck; March 2023. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf Available at.

Tecentriq® (atezolizumab) [prescribing information]. South San Francisco: Genentech; December. 2022. https://www.gene.com/download/pdf/tecentriq_prescribing.pdf Available at.

Reck M., Rodriguez-Abreu D., Robinson A.G., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. PubMed

Paz-Ares L., Luft A., Vicente D., et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. PubMed